Core Insights - Priovant Therapeutics announced positive results from the Phase 3 VALOR trial for brepocitinib in dermatomyositis, published in the New England Journal of Medicine, indicating significant clinical improvements and potential for practice change in treatment [1][4]. Study Results - The VALOR trial enrolled 241 patients across 90 sites globally, achieving its primary endpoint with brepocitinib 30 mg showing a 15.3-point greater improvement in the Total Improvement Score (TIS) at Week 52 compared to placebo (P<0.001) [2][7]. - Brepocitinib 30 mg demonstrated statistically significant improvements across all nine key secondary endpoints, with effects observable as early as Week 4 and sustained through Week 52 [2][7]. - More than two-thirds of patients on brepocitinib 30 mg achieved a TIS40, which is twice the minimum clinically important difference, while over half reduced systemic corticosteroid use to ≤2.5 mg/day [7]. Safety and Tolerability - Serious infections were more common in the brepocitinib 30 mg group compared to placebo, but these events were manageable, and treatment was completed in most cases [3][8]. - Adverse events leading to treatment discontinuation were more frequent in the placebo group, as were malignancies and cardiovascular events, suggesting that these may reflect the baseline risks associated with dermatomyositis [3][8]. Regulatory Status - The U.S. FDA has granted Priority Review for brepocitinib's New Drug Application (NDA), with a target action date set for the third quarter of 2026 [5][9]. Additional Findings - Analyses presented at the 2026 American Academy of Dermatology Meeting highlighted rapid and statistically significant reductions in itch and improvements in skin-related quality of life for patients treated with brepocitinib [5][6]. - Among patients with moderate-to-severe skin disease at baseline, brepocitinib 30 mg was associated with a 26.6% higher rate of functional skin remission compared to placebo [6]. Company Overview - Priovant Therapeutics focuses on developing novel therapies for autoimmune diseases, with brepocitinib being a first-in-class selective inhibitor of TYK2 and JAK1, targeting key cytokines linked to autoimmunity [10]. - The company is also evaluating brepocitinib in other conditions, including non-infectious uveitis and cutaneous sarcoidosis, with ongoing clinical trials [10]. Parent Company - Roivant is the parent company of Priovant Therapeutics, aiming to accelerate the development and commercialization of impactful medicines across various autoimmune indications [11].

Summary of Roivant Sciences Conference Call Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Date**: March 11, 2026 - **Key Speaker**: Matt Gline, CEO Core Industry Insights - **Transformative Period**: Roivant is experiencing a transformative phase, focusing on drug development and indication selection, with a strong pipeline of products ready for launch and data release [6][8] - **Upcoming Launches**: The company anticipates launching a product for dermatomyositis by the end of September 2026, following the acceptance of their NDA with priority review [7] Key Products and Programs - **Brepocitinib**: - Targeting dermatomyositis, an orphan inflammatory disease with high unmet need. The current patient population in the U.S. is estimated at 40,000, with 75% on first-line therapies [24][25] - The drug is positioned as a significant alternative to existing treatments, particularly for patients currently on high-dose corticosteroids [29] - The launch strategy involves building a patient support organization and a qualified field force to ensure effective adoption [20][31] - **Other Indications**: - **Cutaneous Sarcoidosis**: A pivotal program is set to begin, with promising phase 2 results showing a significant improvement in disease activity [32][34] - **Non-Infectious Uveitis (NIU)**: Data from pivotal studies is expected in the second half of 2026, with a patient population of approximately 70,000 [46][48] Market Context and Competitive Landscape - **Market Opportunity**: The company is focusing on orphan diseases where there is a high unmet need, allowing for a different risk-benefit analysis compared to more common conditions [42] - **Safety Profile**: Brepocitinib, while a JAK inhibitor, is expected to have a favorable safety profile in the context of orphan diseases, where the cost-benefit trade-off is more favorable [44] Future Directions - **Expansion of Indications**: Roivant is exploring additional indications for brepocitinib, including pulmonary sarcoidosis and other severe inflammatory conditions [50][52] - **Immunovant Developments**: The company is also developing FcRn inhibitors, with significant upcoming data releases for conditions like cutaneous lupus and treatment-refractory rheumatoid arthritis [86][88] Financial and Operational Strategy - **R&D Focus**: The company emphasizes a rigorous economic approach to R&D, aiming to maximize value from clinical trials and partnerships [15][16] - **Commercial Strategy**: Roivant plans to leverage learnings from other biotech companies to ensure successful commercial launches, particularly in orphan indications [30][31] Conclusion Roivant Sciences is positioned at a pivotal moment with multiple product launches and data readouts on the horizon, focusing on high unmet needs in orphan diseases. The company's strategic approach to drug development and commercialization aims to capitalize on its innovative pipeline and market opportunities.

Summary of Roivant Sciences Conference Call Company and Industry Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Industry**: Biotechnology, specifically focusing on lipid nanoparticles and mRNA vaccine technology Key Points and Arguments 1. **Settlement Announcement**: Roivant announced a global settlement of $2.25 billion with Moderna, resolving patent litigation related to the COVID-19 vaccine [5][6][10] 2. **Payment Structure**: The settlement includes a $950 million upfront payment to be made in July 2026, and a contingent payment of $1.3 billion based on the outcome of a legal appeal regarding Section 1498 [5][6][11] 3. **Market Share Impact**: The settlement covers Moderna's global market share of COVID vaccines, which is approximately one-third of the total market [6][13] 4. **Historical Context**: This settlement is noted as one of the largest outcomes in patent litigation history, with the potential to be the largest paid-out case among those that would have gone to jury [9][10] 5. **Use of Settlement Proceeds**: Roivant plans to invest the settlement proceeds into its current pipeline and upcoming launches, while also expanding its share buyback program to $1 billion [11][12] 6. **Appeal Process**: The appeal regarding Section 1498 is expected to take 18 to 36 months, with Roivant expressing confidence based on previous favorable rulings [13][24] 7. **Pfizer Litigation**: The company is pursuing a similar case against Pfizer-BioNTech, with the expectation that the outcome of the Moderna case may influence negotiations with Pfizer [31][65] 8. **Brepocitinib Update**: Roivant announced that the NDA for brepocitinib was accepted by the FDA with priority review, with a potential launch by the end of September 2026 [15][57] 9. **Capital Allocation Strategy**: Roivant aims to be efficient in capital allocation, balancing share buybacks with investments in new opportunities and existing programs [70][82] Additional Important Information 1. **Legal Precedents**: The settlement with Moderna sets a legal precedent that may impact the ongoing litigation with Pfizer, although Pfizer is not precluded from making its own validity challenges [76] 2. **Future Royalties**: The settlement is structured as a lump sum that covers all future royalties, eliminating the need for additional payments [51] 3. **Market Preparation for Brepocitinib**: Roivant is actively preparing for the launch of brepocitinib, including building a field force for medical engagement and patient education [78][57] 4. **Investor Relations**: Roivant encourages investors to review SEC filings for more information on forward-looking statements and associated risks [2] This summary encapsulates the critical aspects of Roivant Sciences' recent conference call, highlighting the significant settlement with Moderna, ongoing litigation with Pfizer, and strategic plans for future growth and capital allocation.

Summary of Roivant Sciences FY Conference Call (March 03, 2026) Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: 46th Annual TD Cowen Healthcare Conference Key Points PDUFA Date and Drug Launch - The PDUFA date for Roivant's therapy is set for the third quarter of 2026, with a planned launch by the end of September 2026 [6][8] - The company received a priority review from the FDA, indicating confidence in the therapy's data quality [10] Market Expectations and Physician Feedback - Surveys indicate that physicians expect a 30% market share for the new therapy, which aligns with historical accuracy of such surveys [12][13] - There is significant excitement among physicians regarding the potential to reduce steroid burden for patients [16] Treatment Landscape - Approximately 75% of the 40,000 patients tracked are currently managed with DMARDs and oral steroids, while 25% are on IVIG or off-label treatments [17][18] - The new therapy is expected to attract patients dissatisfied with current treatments, particularly those with high steroid burdens [19][20] Efficacy and Labeling - The therapy is anticipated to have a broad indication for dermatomyositis, aiming to serve a wide patient population [13][14] - The study included a steroid taper, and the company plans to provide extensive information on managing steroid reduction [15] Clinical Trials and Data - The NEPTUNE study showed a 29% relapse rate at the 45 mg dose, significantly better than Humira's 62% [23] - The CLARITY studies are designed to mirror NEPTUNE, with a focus on steroid tapering [24][26] Future Studies and Approvals - The company is preparing for phase 3 studies based on positive phase 2 data, with discussions ongoing with the FDA regarding trial design [48][49] - The goal is to maintain consistency with successful phase 2 data in future studies [49] Mosliciguat and Other Programs - Mosliciguat is being studied for pulmonary hypertension with promising phase 1 data showing significant peripheral vascular resistance reduction [61] - The phase 2b PHOCUS study is expected to read out data in the second half of the year, focusing on PVR and six-minute walk metrics [62][64] IMVT-1402 for Graves' Disease - Data from the FORWARD studies for Graves' disease is expected next year, with a focus on controlling refractory patients [82][83] - The therapy aims to provide a new treatment option for patients who are currently uncontrolled on antithyroid drugs (ATDs) [82][84] Legal Matters - Ongoing litigation with Moderna regarding intellectual property, with the company feeling confident about its position [92][93] Additional Insights - The company is focused on addressing the needs of patients who are currently dissatisfied with existing therapies, particularly in underdeveloped treatment landscapes [20][73] - There is a strong emphasis on the importance of patient comfort and the potential for new therapies to improve quality of life [70][72]

Core Insights - Priovant Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for brepocitinib for treating dermatomyositis and granted it Priority Review status, with a target action date set for Q3 2026 and a potential launch at the end of September 2026 [1][6] Group 1: FDA Review and Study Results - The Priority Review designation was based on the significant unmet medical need in dermatomyositis and positive results from the Phase 3 VALOR study, which was the longest and largest interventional trial in this area [2][6] - The VALOR study enrolled 241 subjects and demonstrated that brepocitinib 30 mg resulted in statistically significant improvements in the myositis Total Improvement Score (TIS) at Week 52 compared to placebo, with benefits observed as early as Week 4 [4][6] - More than two-thirds of patients on brepocitinib 30 mg achieved a TIS40, which is twice the minimum clinically important difference, while over half also maintained a steroid dependency of ≤2.5 mg/day [4][6] Group 2: Patient Impact and Company Commitment - The medical community has expressed excitement over the potential for brepocitinib to be the first targeted therapy approved for dermatomyositis, addressing a long-standing need for innovative treatments [3][4] - The CEO of Priovant emphasized the company's commitment to working closely with the FDA to expedite the availability of brepocitinib for patients [4][8] Group 3: Safety and Broader Development - The safety profile of brepocitinib appears similar to that of approved JAK and TYK2 inhibitors, with serious infections noted in the 30 mg group but manageable with medical intervention [5][7] - Priovant is also developing brepocitinib for other conditions, including non-infectious uveitis and cutaneous sarcoidosis, indicating a broader therapeutic potential for this compound [8]

Group 1 - Roivant Sciences Ltd. (NASDAQ:ROIV) is considered a promising low-cost stock, with multiple firms raising their price targets following positive Phase 2 data for brepocitinib in cutaneous sarcoidosis [1][2][3] - Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy rating, citing the drug's growth potential and integrating revenue projections into its financial model [1][4] - H.C. Wainwright also increased its price target to $33 from $26, characterizing the Phase 2 data as impressive and adding this indication to its valuation model [2] - Bank of America raised its price target to $26 from $22 with a Neutral rating, noting that the FQ3 2026 results were in line and highlighting the positive Phase 2 topline results of brepocitinib [3]

Market Overview - Richard Bernstein, CEO of Richard Bernstein Advisors, discussed the equity markets on CNBC, noting a significant broadening of the market since late October 2025 [1] - The unexpected strength of the overall economy has contributed to this shift, with nominal GDP exceeding 8% last quarter, a level not seen since 2006, excluding the post-pandemic period [2] Investment Strategy - Bernstein emphasized a macro-focused investment strategy, avoiding individual stock picks, and questioned the rationale behind paying high valuations for well-known tech stocks when similar growth can be found at lower valuations globally [3] Promising Low-Cost Stocks - A list of 11 promising low-cost stocks was compiled, focusing on those priced between $10 and $30 and favored by elite hedge funds [6] - The strategy of imitating top hedge fund stock picks has historically outperformed the market, with a reported return of 427.7% since May 2014 [7] Company Highlights Roivant Sciences Ltd. (NASDAQ:ROIV) - Roivant Sciences is highlighted as a promising low-cost stock, with a price target raised by Citi to $35 from $26 due to positive Phase 2 data for brepocitinib [8][9] - H.C. Wainwright also increased its price target for Roivant to $33, citing impressive Phase 2 data [9] - Bank of America raised its price target to $26 from $22, noting that FQ3 2026 results were in line with expectations [10] News Corporation (NASDAQ:NWSA) - News Corporation is also listed as a promising low-cost stock, with a recent price target adjustment by Citi to $39 from $40 while maintaining a Buy rating [12] - The company reported a 6% revenue increase to $2.4 billion and a 9% expansion in total segment EBITDA to $521 million for FQ2 2026 [13] - Despite a 21% decline in net income from continuing operations, adjusted EPS rose to $0.40, and profitability margins improved to 22.1% [13] - Performance was driven by the Dow Jones and Digital Real Estate segments, while the News Media segment faced challenges [14]

Core Insights - Roivant Sciences Ltd. (NASDAQ:ROIV) is recognized as a promising healthcare stock under $50, with a revised price target of $38 from TD Cowen, maintaining a Buy rating following positive Phase 2 results for brepocitinib in cutaneous sarcoidosis [1][2] Financial Performance - The company reported $4.5 billion in consolidated cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2025, indicating a strong cash runway towards profitability [3] Product Development - Brepocitinib 45 mg showed significant improvement in cutaneous sarcoidosis disease activity, with rapid and sustained efficacy across all measured endpoints and a consistent safety profile [2] - An NDA has been submitted to the FDA for brepocitinib in dermatomyositis, with topline data from Phase 3 studies in non-infectious uveitis expected in the second half of 2026 [2] - The company is actively exploring additional indications for brepocitinib [2] Product Portfolio - Roivant Sciences Ltd. develops transformative medicines, with a product portfolio that includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, targeting various therapeutic areas such as oncology, immunology, dermatology, and hematology [4]

Financial Data and Key Metrics Changes - The company reported a non-GAAP net loss of $167 million for the quarter, with R&D expenses at $165 million and G&A expenses at $175 million [30] - The company maintains a strong cash position with $4.5 billion in consolidated cash, providing ample capital to reach profitability [30] Business Line Data and Key Metrics Changes - The NDA for brepocitinib in dermatomyositis has been submitted, and the phase 2b study for 1402 in D2T-RA has fully enrolled [6][7] - The phase 2 study for mosliciguat in PH-ILD has also fully enrolled, with top-line data expected in the second half of the year [7][8] Market Data and Key Metrics Changes - The company is targeting a large addressable patient population for brepocitinib, particularly in orphan inflammatory diseases with high unmet needs [25][36] - The potential market for cutaneous sarcoidosis is estimated to be slightly smaller than dermatomyositis, with around 40,000 eligible patients [79] Company Strategy and Development Direction - The company is focused on expanding the development of brepocitinib into additional indications, emphasizing its potential as a first-in-class therapy for sarcoidosis [35][36] - The company plans to leverage insights from the phase 2 study to inform the design of the phase 3 trial, aiming for a similar size and endpoint duration [79] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the strong phase 2 data for brepocitinib, highlighting its potential to address significant patient needs [25][36] - The company anticipates a busy year ahead with multiple pivotal study readouts and potential commercial launches [30][31] Other Important Information - The jury trial against Moderna is scheduled for March 9, with recent favorable decisions regarding summary judgment [29] - The company is exploring further development opportunities for brepocitinib, including other forms of sarcoidosis and related conditions [35][36] Q&A Session Summary Question: What are the further development opportunities for brepocitinib? - Management is enthusiastic about expanding brepocitinib's development, particularly in large orphan markets with high unmet needs [35][36] Question: Can you provide more details on the baseline characteristics of the CSAMI numbers? - There were significant differences in baseline characteristics, including disease duration and morphology, which may have influenced the results [42][43] Question: What is the pricing strategy for brepocitinib? - Pricing has not been finalized, but it is expected to be positioned within the orphan drug pricing envelope [48][50] Question: What are the expectations for the phase 3 trial design? - The phase 3 trial is expected to be similar in size to the phase 2 trial, with final details to be discussed with the FDA [58][79] Question: What percentage of patients in the Beacon study had organ involvement? - Approximately 60% of patients had pulmonary involvement, and exploratory endpoints related to organ involvement were collected but not analyzed yet [83][84]

Financial Data and Key Metrics Changes - The company reported a non-GAAP net loss of $167 million for the quarter, with R&D expenses at $165 million and G&A expenses at $175 million [30] - The company maintains a strong cash position with $4.5 billion in consolidated cash, providing ample capital to reach profitability and pursue additional opportunities [30] Business Line Data and Key Metrics Changes - The NDA for brepocitinib in dermatomyositis has been submitted, and the phase IIb study for 1402 in D2T-RA has fully enrolled [6][7] - The phase II study for mosliciguat in PH-ILD has also fully enrolled, with top-line data expected in the second half of the year [7][28] Market Data and Key Metrics Changes - The company is targeting a large addressable patient population for brepocitinib, particularly in orphan inflammatory diseases with high unmet needs [25][36] - The company estimates around 40,000 eligible patients for cutaneous sarcoidosis, indicating a significant market opportunity [77] Company Strategy and Development Direction - The company is focused on expanding the development of brepocitinib into additional indications, emphasizing its potential as a first-in-class therapy for sarcoidosis [35][36] - The company plans to leverage insights from the phase II study to inform the design of the phase III trial, aiming for a similar size and endpoint duration [79] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the strong phase II data for brepocitinib, highlighting its potential to address significant patient needs in various indications [25][36] - The company anticipates a catalyst-rich period ahead, with multiple NDA and BLA filings expected in the coming years [31] Other Important Information - The jury trial against Moderna is scheduled for March 9, with recent favorable decisions regarding summary judgment [29] - The company is exploring further development opportunities for brepocitinib, including potential expansion into other forms of sarcoidosis [36][84] Q&A Session Summary Question: What are the further development opportunities for brepocitinib? - Management is enthusiastic about further development and is considering additional indications, emphasizing the strong data supporting brepocitinib's efficacy [35] Question: Can you provide more details on the baseline characteristics of the CSAMI numbers? - Management noted that there were some significant differences in baseline characteristics, including disease duration and morphology, which may have influenced the results [42][43] Question: What is the pricing strategy for brepocitinib? - Management has not finalized pricing but indicated it will be positioned as an orphan-priced drug, with considerations based on existing therapies [48][50] Question: What is the expected size and design of the phase III study? - Management indicated that the phase III study would likely be similar in size to the DM trial, with final details to be determined after discussions with the FDA [59][79] Question: What percentage of patients in the Brepo study had organ involvement? - Approximately 60% of patients had pulmonary involvement, and around 30% had other organ involvement, primarily ocular [84]